Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease

NCT06691529 | Not Yet Recruiting

• 1 other identifier: fatty liver disease
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

The association of metabolic associated fatty liver disease in patients with chronic glomerular disease

Conditions

Fatty Liver Disease; Chronic Glomerular Disease

Outcome Measures

Primary Outcomes (1)

• association between metabolic associated fatty liver disease and chronic kidney disease

  To detect the association between metabolic associated fatty liver disease and chronic kidney disease with glomerular diseaese in Assuit university hospital.

  through study completion, an average of 1 year

Study Arms (1)

study group

500 patients presented at Nephrology unit/Internal Medicine department (Assiut University Hospital) In the period 2024-2026.

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients in this study will be subjected to 1. Detailed history and full clinical examination 2. Anthropometric measurements; Hight, weight, waist circumference. 3. Full lab investigations (Complete blood picture , kidney function tests, liver function tests, serum electrolytes, Ferritin, Uric acid level, Prothrombin time and concentration and serum albumin) 4. High sensitivity CRP 5. lipid profile (Fasting) 6. urine analysis, ACR. 7. Available documented renal biopsy 8. HBA1c 9. C- peptide levels. 10. FIB4 - score

You may qualify if:

• All CKD patient aging between (18-70) years with known tubule-glomerular diseases.
• At any eGFR.
• All CKD patient have either type I/II DM associated with CKD .

You may not qualify if:

• CKD patients of Unknown etiology.
• CKD patients with liver cirrhosis.
• CKD patients secondry to documented diabetic nephropathy.
• Patients with previous/current HBV or HCV.
• Pregnant CKD patients.
• Patient commencing any hepatotoxic medication.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty Liver; Liver Diseases; Digestive System Diseases

Central Study Contacts

Samar Fahmy Amin

CONTACT

01004084187; elamin67@aun.edu.eg

Hussein Ahmed El_Amin

CONTACT

01004084187; elamin67@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: physician

Study Record Dates

• First Submitted: November 14, 2024
• First Posted: November 15, 2024
• Study Start: December 1, 2024
• Primary Completion: December 1, 2025
• Study Completion: March 1, 2026
• Last Updated: November 18, 2024

Record last verified: 2024-11